Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: A phase I/II study conduct by the Hellenic Cooperative Oncology Group (HeCOG)

Anti-Cancer Drugs

Volumn 15, Issue 5, 2004, Pages 479-487

  Janinis, Jinn ^a,i   Stathopoulos, George P ^b   Nikolaidis, Pavlos ^c   Kalofonos, Haralambos P ^d   Kalogera Fountzila, Anna ^c   Samantas, Epaminondas ^e   Aravantinos, Gerasimos ^e   Anagnostopoulos, Athanassios ^f   Tolis, Christos ^g   Makatsoris, Thomas ^d   Rigatos, Sotiris K ^b   Bafaloukos, Dimitrios ^h   Dimopoulos, Meletios A ^f   Daniilidis, John ^c   Fountzilas, George ^c  

^a Social Security Org Oncology Center   (Greece)

^b Henry Dynan Hospital   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d UNIVERSITY OF PATRAS   (Greece)

^e AGII ANARGIRI CANCER HOSPITAL   (Greece)

^f UNIVERSITY OF ATHENS   (Greece)

^g UNIVERSITY OF IOANNINA   (Greece)

^h METROPOLITAN HOSPITAL   (Greece)

ⁱ NONE   (Greece)

Author keywords

Chemotherapy; Head and neck cancer; Paclitaxel; Pegylated liposomal doxorubicin

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BLEEDING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG RESPONSE; FEMALE; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEART ARRHYTHMIA; HUMAN; HYPERSENSITIVITY; INFECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NASOPHARYNX TUMOR; NEUROTOXICITY; NEUTROPENIA; POPULATION RESEARCH; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; PACLITAXEL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 2942522719     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000127662.81719.86     Document Type: Article

References (36)

1. Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol 1999; 17:3512-3521.
2. Buntzel J, Weinaug R, Glatzel M, et al. Pegylated liposomal doxorubicin (CAELYX) in the treatment of advanced head and neck cance - results of a phase I/II study. Proc Am Soc Clin Oncol 1999; 1540a.
3. Harrington KJ, Lewanski C, Northcote AD, et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cancer 2001; 37:2015-2022.
4. Rigatos SK, Tsavdaridis D, Athanasiadis A, Stathopoulos JG, Stathopoulos GP. Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: a phase II study. Oncol Rep 2003; 10:1817-1819.
5. Campos SM, Matulonis UA, Penson RT, et al. Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mullerian tumors. Gynecol Oncol 2003; 90:610-618.
6. Caponigro F, Cornelia P, Budillon A, et al. phase I study of Caelyx (doxorubicin HCl, pegylated liposomal) in recurrent or metastatic head and neck cancer. Ann Oncol 2000; 11:339-342.
7. Goldspiel BR. Clinical overview of the taxanes. Pharmacotherapy 1997; 17:1103-1253.
8. Loeffler T, Freund W, Lipke J. Schedule and dose intensified paclitaxel as weekly one hour infusion. Evidence for an improved toxicity profile and response activity in pretreated solid tumors. Proc Am Soc Clin Oncol 1995; 14:470.
9. Smith RE, Thornton DE, Allen J. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol 1995; 22:41-46.
10. Forastiere AA, Shank D, Neuberg D, et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998; 82:2270-2274.
11. Fountzilas G, Stathopoulos G, Nicolaides C, et al. Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1999; 10:475-478.
12. Benasso M, Numico G, Merlano M, et al. Phase I-II study of Taxol, cisplatin (CDDP) and fluorouracil (FU) in relapsed squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 1997; 1415a.
13. Hussain M, Salwen W, Kucuk O, et al. Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report. Semin Oncol 1997; 24(suppl 19):43-45.
14. Hainsworth JD, Meluch AA, Greco FA. Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: preliminary results of phase II trial. Semin Oncol 1997; 24(suppl 19):38-42.
15. Shin DM, Glisson BS, Khuri FR, et al. phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16:1325-1330.
16. Forastiere AA, Leong T, Rowinsky E, et al. phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 2001; 19: 1088-1095.
17. Fountzilas G, Skarlos D, Athanassiades A, et al. Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1997; 8:451-415.
18. Stathopoulos GP, Rigatos S, Papakostas P, et al. Effectiveness of paclitaxel and carboplatin combination in heavily pretreated patients with head and neck cancers. Eur J Cancer 1997; 33:1780-1783.
19. Clark JI, Hofmeister C, Choudhury A, et al. phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Cancer 2001; 92:2334-2340.
20. Willey TA, Bekos EJ, Gaver RC, et al. High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. J Chromatogr 1993; 621:231-238.
21. Gabizon AA, Barenholz Y, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 1993; 10:703-708.
22. Huizing MT, Keung AC, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993; 11:2127-2135.
23. Coukell AJ, Spencer CM. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. Drugs 51997; 3:520-538.
24. Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics. Philadelphia, PA: Lea & Febiger; 1984.
25. Gibaldi M, Perier D. Pharmacokinetics. New York: Marcel Dekker; 1990.
26. Common Toxicity Criteria, 2nd edn. Bethesda. MD: Cancer Therapy Evaluation Program, National Cancer Institute; 1999.
27. WHO. Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication 48. Geneva: WHO; 1972.
28. Peto R, Peto J. Asymptomatically efficient rank invariant test procedures [with Discussion]. J R Stat Soc 1972; 135:185-206.
29. Parker R, Lee K, Dabholkar M. Influence of Taxol: cisplatin sequencing on cisplatin-DNA adduct repair in human ovarian cancer cells. Proc Am Ass Cancer Res 1993; 34:356.
30. Venturini M, Lunardi G, Del Mastro L, et al. Sequence effect of epirubicin and paclitaxel treatment on Pharmacokinetics and toxicity. J Clin Oncol 2000; 18:2116-2125.
31. Holmes FA, Madden T, Newman RA, et al. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1996; 14:2713-2721.
32. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993; 328:184-194.
33. Schantz S, Harrison L, Forastiere A. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: DeVita V, Hellman S, Rosenberg S (editors): Cancer: Principles and Practice of Oncology, 5th edn. Philadelphia, PA: Lippincott-Raven; 1997, pp. 741-801;
34. Papadimitrakopoulou VA, Dimery IW, Lee JJ, et al. Cisplatin, fluorouracil, and I-leucovorin induction chemotherapy for locally advanced head and neck cancer: the MD Anderson Cancer Center experience. Cancer J Sci Am 1997; 3:92-99.
35. Dunphy F, Boyd J, Dunleavy T. Paclitaxel and carboplatin in head and neck cancer. Semin Oncol 1997; 24(suppl 19):25-27.
36. Leonard CE, Chan DC, Chou TC, et al. Paclitaxel enhances in vitro radiosensitivity of squamous cell carcinoma cell lines of the head and neck. Cancer Res 1996; 56:5198-5204.